...
首页> 外文期刊>Drug Metabolism and Disposition: The Biological Fate of Chemicals >The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide–Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy
【24h】

The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide–Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy

机译:抗菌剂夫西地酸抑制有机阴离子转运多肽介导的肝清除,并可能增强他汀类药物引起的肌病

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Chronic treatment of methicillin-resistant Staphylococcus aureus strains with the bacteriostatic agent fusidic acid (FA) is frequently associated with myopathy including rhabdomyolysis upon coadministration with statins. Because adverse effects with statins are usually the result of drug–drug interactions, we evaluated the inhibitory effects of FA against human CYP3A4 and clinically relevant drug transporters such as organic anion transporting polypeptides OATP1B1 and OATP1B3, multidrug resistant protein 1, and breast cancer resistance protein, which are involved in the oral absorption and/or systemic clearance of statins including atorvastatin, rosuvastatin, and simvastatin. FA was a weak reversible (IC50 = 295 ± 1.0 μM) and time-dependent (KI = 216 ± 41 μM and kinact = 0.0179 ± 0.001 min?1) inhibitor of CYP3A4-catalyzed midazolam-1′-hydroxylase activity in human liver microsomes. FA demonstrated inhibition of multidrug resistant protein 1–mediated digoxin transport with an IC50 value of 157 ± 1.0 μM and was devoid of breast cancer resistance protein inhibition (IC50 > 500 μM). In contrast, FA showed potent inhibition of OATP1B1- and OATP1B3-specific rosuvastatin transport with IC50 values of 1.59 μM and 2.47 μM, respectively. Furthermore, coadministration of oral rosuvastatin and FA to rats led to an approximately 19.3-fold and 24.6-fold increase in the rosuvastatin maximum plasma concentration and area under the plasma concentration–time curve, respectively, which could be potentially mediated through inhibitory effects of FA on rat Oatp1a4 (IC50 = 2.26 μM) and Oatp1b2 (IC50 = 4.38 μM) transporters, which are responsible for rosuvastatin uptake in rat liver. The potent inhibition of human OATP1B1/OATP1B3 by FA could attenuate hepatic uptake of statins, resulting in increased blood and tissue concentrations, potentially manifesting in musculoskeletal toxicity
机译:用抑菌剂夫西地酸(FA)长期治疗耐甲氧西林的金黄色葡萄球菌菌株通常与肌病有关,包括与他汀类药物合用时的横纹肌溶解。因为他汀类药物的不良反应通常是药物相互作用的结果,所以我们评估了FA对人CYP3A4和临床相关药物转运蛋白(如有机阴离子转运多肽OATP1B1和OATP1B3,多药耐药蛋白1和乳腺癌耐药蛋白)的抑制作用,这与他汀类药物(包括阿托伐他汀,瑞舒伐他汀和辛伐他汀)的口服吸收和/或全身清除有关。 FA是人肝微粒体中CYP3A4催化的咪达唑仑1'-羟化酶活性的弱可逆性(IC50 = 295±1.0μM)和时间依赖性(KI = 216±41μM且运动因子= 0.0179±0.001 min?1) 。 FA表现出对多药耐药蛋白1介导的地高辛转运的抑制作用,IC50值为157±1.0μM,并且没有乳腺癌耐药蛋白抑制作用(IC50> 500μM)。相反,FA显示出对OATP1B1和OATP1B3特异性瑞舒伐他汀转运的有效抑制,IC50值分别为1.59μM和2.47μM。此外,对大鼠口服瑞舒伐他汀和FA共同给药会导致瑞舒伐他汀最大血浆浓度和血浆浓度-时间曲线下面积分别增加约19.3倍和24.6倍,这可能是通过FA的抑制作用来介导的大鼠Oatp1a4(IC50 = 2.26μM)和Oatp1b2(IC50 = 4.38μM)转运蛋白,它们负责罗苏伐他汀在大鼠肝脏中的摄取。 FA对人OATP1B1 / OATP1B3的有效抑制作用可能会降低他汀类药物的肝吸收,导致血液和组织浓度增加,并可能表现为肌肉骨骼毒性

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号